Annovis Chairman of the Board invested $5.0 million as part of the underwritten public offering Company expects cash to fund operations through the pivotal Phase 3 Alzheimer’s data readout in March 2027 MALVERN, Pa.,
MALVERN, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy,
MALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy,
MALVERN, Pa., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy,
MALVERN, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy,
MALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy,
MALVERN, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy,
MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy,
Pivotal Phase 3 Alzheimer’s disease (AD) trial is fully enrolled with a total number of 850 patients, exceeding original projections.Parkinson’s disease (PD) open-label extension (OLE) study has enrolled 266 patients
Pivotal Phase 3 trial enrolls 850 patients, exceeding original projections Study completion on track: symptomatic data readout - Q1 2027, disease-modifying data readout - Q1 2028 Company positions for two NDA
MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy,
MALVERN, Pa., May 26, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for
MALVERN, Pa., May 20, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for
MALVERN, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for
Phase 3 AD trial: 85% of patients enrolled; full enrollment on track in summer 2026PD open-label extension (OLE) study: 40% of patients enrolled; full enrollment on track in fourth quarter 2026New Drug Application (NDA)
